Case Report and Genomic Analysis of Cefiderocol-Resistant Escherichia coli Clinical Isolates.
AP infectious disease
CP microbiology
Molecular diagnostics
Journal
American journal of clinical pathology
ISSN: 1943-7722
Titre abrégé: Am J Clin Pathol
Pays: England
ID NLM: 0370470
Informations de publication
Date de publication:
03 Feb 2022
03 Feb 2022
Historique:
received:
13
04
2021
accepted:
01
06
2021
pubmed:
21
9
2021
medline:
11
3
2022
entrez:
20
9
2021
Statut:
ppublish
Résumé
Cefiderocol is a novel siderophore cephalosporin with in vitro activity against multidrug-resistant (MDR), gram-negative bacteria and intrinsic structural stability to all classes of carbapenemases. We sought to identify gene variants that could affect the mechanism of action (MOA) of cefiderocol. We report a case of bacteremia in a liver transplant candidate with a strain of carbapenem-resistant Escherichia coli that was found to be resistant to cefiderocol despite no prior treatment with this antimicrobial agent. Using whole-genome sequencing, we characterized the genomic content of this E coli isolate and assessed for genetic variants between related strains that were found to be cefiderocol susceptible. We identified several variants in genes with the potential to affect the mechanism of action of cefiderocol. The cefiderocol resistance in the E coli isolate identified in this study is likely due to mutations in the cirA gene, an iron transporter gene.
Identifiants
pubmed: 34542575
pii: 6372662
doi: 10.1093/ajcp/aqab115
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cephalosporins
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
257-265Informations de copyright
© American Society for Clinical Pathology, 2021. All rights reserved.For permissions, please e-mail: journals.permissions@oup.com.